Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.286 USD | -4.98% | -15.65% | -79.49% |
Mar. 19 | Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected | MT |
Mar. 19 | Seelos Therapeutics' ALS treatment fails in mid-stage study | RE |
Financials (USD)
Sales 2022 | - | Sales 2023 | 2.2 | Capitalization | 13.61M |
---|---|---|---|---|---|
Net income 2022 | -73M | Net income 2023 | -37M | EV / Sales 2022 | - |
Net Debt 2022 | 4.59M | Net Debt 2023 | 11.23M | EV / Sales 2023 | 11,278,477 x |
P/E ratio 2022 |
-0.98
x | P/E ratio 2023 |
-0.18
x | Employees | 16 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98% |
Latest transcript on Seelos Therapeutics, Inc.
1 day | -4.98% | ||
1 week | -15.65% | ||
Current month | -51.76% | ||
1 month | -42.28% | ||
3 months | -72.85% | ||
6 months | -95.58% | ||
Current year | -79.49% |
Managers | Title | Age | Since |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 86-12-31 |
Director of Finance/CFO | 52 | 18-12-31 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 21-08-31 | |
Richard Pascoe
BRD | Director/Board Member | 60 | 13-02-28 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 18-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 0.285 | -5.32% | 121 974 |
24-04-24 | 0.301 | -7.98% | 612,932 |
24-04-23 | 0.3271 | +0.43% | 383,907 |
24-04-22 | 0.3257 | -2.63% | 204,336 |
24-04-19 | 0.3345 | -1.04% | 287,847 |
Delayed Quote Nasdaq, April 25, 2024 at 10:47 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-79.49% | 4.12M | |
-3.32% | 104B | |
+0.05% | 97.42B | |
+1.46% | 22.2B | |
-18.28% | 21.23B | |
-10.72% | 18.33B | |
-42.33% | 16.35B | |
-17.29% | 15.06B | |
+3.57% | 13.98B | |
+27.78% | 11.66B |
- Stock Market
- Equities
- SEEL Stock